CAR T-cell therapy Carvykti shows promise in early myeloma
A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who hadn’t fully responded to a standard autologous stem cell transplant (ASCT). That’s according to new data from the 17 patients in cohort D of the…